Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Virol J ; 12: 23, 2015 Feb 13.
Article in English | MEDLINE | ID: mdl-25886491

ABSTRACT

BACKGROUND: BK polyomavirus infects most of the general population. However, its clinical manifestations are almost exclusively seen in immunocompromised patients, particularly in kidney and hematopoietic stem cell transplantation recipients. CASE PRESENTATION: A 15-y-old female suffering from common B-cell acute lymphoblastic leukaemia underwent hematopoietic stem cell transplantation. The patient had reactivation of BKPyV infection and developed an haemorrhagic cystitis. Three months after transplant, BKPyV viremia and viruria increased and she developed a severe nephropathy associated to a polyclonal gammopathy with high levels of isolated IgM. CONCLUSION: This case report describes a rare and unexpected polyclonal gammopathy developed during a polyomavirus-associated nephropathy confirmed by immunohistochemical and laboratory analyses.


Subject(s)
Antibodies, Viral/immunology , BK Virus/physiology , Hematopoietic Stem Cell Transplantation/adverse effects , Kidney Diseases/etiology , Leukemia, B-Cell/therapy , Plasma Cells/cytology , Polyomavirus Infections/immunology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adolescent , BK Virus/immunology , Female , Humans , Kidney Diseases/immunology , Kidney Diseases/virology , Leukemia, B-Cell/complications , Plasma Cells/immunology , Polyomavirus Infections/etiology , Polyomavirus Infections/virology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications
2.
Pediatr Blood Cancer ; 62(7): 1202-8, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25631333

ABSTRACT

BACKGROUND: Teratomas demonstrate a benign clinical behavior, however they may recur with malignant components or as teratoma, and in a small group of patients prognosis could be fatal. After the first Italian study, we collected cases of teratoma, alongside the protocol for malignant germ cell tumors. PROCEDURE: Patients with teratoma were collected from 2004 to 2014. Teratomas were classified according to the WHO classifications, as mature and immature. Patients with pathological aFP and/or bHCG, and those with a malignant germ cell component were not included. RESULTS: The study enrolled 219 patients (150 mature, 69 immature teratomas) with a median age at diagnosis of 42 months. The primary sites involved were: 118 gonadal and 101 extragonadal teratomas. Two females with ovarian teratoma had a positive family history. Complete and incomplete surgeries were performed in 85% and 9% of cases. Seventeen events occurred: six females had a second metachronous tumor (5 contralateral ovarian teratoma, 1 adrenal neuroblastoma) and 11 teratomas relapsed/progressed (3 mature, 8 immature teratomas). Two patients died, one of progressive immature teratoma and one of surgical complications. At a median follow up of 68 months, the event-free, relapse-free, and overall survival rates were 90.6%, 94.3%, 98.6%, respectively. CONCLUSIONS: Teratomas show a good prognosis, especially the mature ones: surgery and follow-up remain the standard approach. Incomplete surgery in immature teratoma is the group at greatest risk of relapse. Bilateral ovarian tumors are a possibility, and the rare family predisposition to ovarian mature teratoma warrants further analyses.


Subject(s)
Neoplasm Recurrence, Local/epidemiology , Neoplasms, Second Primary/epidemiology , Neuroblastoma/epidemiology , Ovarian Neoplasms/epidemiology , Teratoma/epidemiology , Testicular Neoplasms/epidemiology , Adolescent , Adult , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Incidence , Infant , Infant, Newborn , Italy/epidemiology , Male , Neoplasm Grading , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Neoplasms, Second Primary/mortality , Neoplasms, Second Primary/pathology , Neuroblastoma/mortality , Neuroblastoma/pathology , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Prognosis , Prospective Studies , Survival Rate , Teratoma/mortality , Teratoma/pathology , Testicular Neoplasms/mortality , Testicular Neoplasms/pathology , Young Adult
3.
APMIS ; 123(1): 77-80, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25131855

ABSTRACT

Varicella zoster virus (VZV), a threat for hematopoietic stem cell transplantation (HSCT) recipients, is still one of the most common viral pathogens that affect these patients with a reported incidence ranging between 17% and 50% in the post transplantation period. Valganciclovir (V-GCV), a valine ester pro-drug of GCV orally administrable, has recently shown great activity against CMV infections, but there are no reports of its clinical efficacy against VZV. We here report a case history of a patient with positive serologic test for VZV, who underwent allogeneic HSCT and developed an atypical varicella-like illness. First-line therapy with foscarnet had to be discontinued due rapid development of renal impairment (creatinine: 2.60 mg/dL, urea: 130.6 mg/dL) and therefore was switched to V-GCV. The renal impairment and skin lesions of the patient fully recovered after few days of therapy, even though the patient had complete lymphocyte depletion. This is the first case of a patient with chickenpox-like illness treated successfully with V-GCV.


Subject(s)
Acute Kidney Injury/chemically induced , Bone Marrow Transplantation/adverse effects , Ganciclovir/analogs & derivatives , Herpes Zoster/drug therapy , Herpesvirus 3, Human/growth & development , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adolescent , Fatal Outcome , Female , Ganciclovir/therapeutic use , Humans , Valganciclovir , Viral Load
4.
J Pediatr Hematol Oncol ; 37(3): e194-7, 2015 Apr.
Article in English | MEDLINE | ID: mdl-24942030

ABSTRACT

Teno Torque virus, member of the family of Anelloviridae, has been associated with many autoimmune diseases such as idiopathic hepatitis, systemic lupus erythematosus, and multiple sclerosis. Its viral load tends to be higher in the bone marrow and in tissues with high turnover rate. We report here a case of an 11-month-old infant affected by acute myeloid leukemia who underwent hematopoietic stem cell transplantation, and after 6 months had autoimmune hepatitis and atopic dermatitis. Extremely high-cytokine IP-10 and eotaxin levels were found in her sera, and serological tests and RT-PCR for viruses showed positive results exclusively for Teno Torque virus.


Subject(s)
Autoimmune Diseases/etiology , Autoimmunity/immunology , DNA Virus Infections/virology , Dermatitis, Atopic/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Hepatitis/etiology , Leukemia, Myeloid, Acute/immunology , Torque teno virus/pathogenicity , Autoimmune Diseases/drug therapy , Autoimmune Diseases/pathology , DNA Virus Infections/immunology , DNA Virus Infections/pathology , DNA, Viral/genetics , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/pathology , Female , Hepatitis/drug therapy , Hepatitis/pathology , Humans , Infant , Leukemia, Myeloid, Acute/therapy , Leukemia, Myeloid, Acute/virology , Prognosis , Torque teno virus/genetics , Torque teno virus/isolation & purification , Viral Load
5.
Pediatr Transplant ; 18(3): E96-9, 2014 May.
Article in English | MEDLINE | ID: mdl-24483599

ABSTRACT

Hurler syndrome type 1 (MPS-1) is an autosomal recessive lysosomal disorder due to the deficiency of the enzyme alpha-L-iduronidase which is necessary for the degradation of dermatan and heparan sulfate. It is characterized by deposit of glycosaminoglycans in tissues, progressive multisystem dysfunction, and early death. HSCT for children with MPS-I is effective, resulting in increased life expectancy and improvement of clinical parameters. The spinal MRI performed on a female 10 yr old undergoing HSCT at the age of 18 months and receiving ERT revealed a considerable decrease in soft tissue around the tip of odontoid causing a significant reduction in spinal cord compression. In light of this result, we suppose that combined ERT and HSCT are successful in Hurler I disease.


Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Iduronidase/therapeutic use , Mucopolysaccharidosis I/therapy , Spinal Cord Compression/therapy , Bone Marrow Transplantation , Child , Enzyme Replacement Therapy/methods , Female , Glycosaminoglycans/urine , Humans , Iduronidase/urine , Magnetic Resonance Imaging , Odontoid Process/physiopathology , Treatment Outcome
6.
Blood ; 123(10): 1470-8, 2014 Mar 06.
Article in English | MEDLINE | ID: mdl-24415536

ABSTRACT

The outcome of high-risk (HR) acute lymphoblastic leukemia patients enrolled in the AIEOP-BFM ALL 2000 study in Italy is described. HR criteria were minimal residual disease (MRD) levels ≥10(-3) at day 78 (MRD-HR), no complete remission (CR) at day 33, t(4;11) translocation, and prednisone poor response (PPR). Treatment (2 years) included protocol I, 3 polychemotherapy blocks, delayed intensification (protocol IIx2 or IIIx3), cranial radiotherapy, and maintenance. A total of 312 HR patients had a 5-year event-free survival (EFS) of 58.9% (standard error [SE] = 2.8) and an overall survival of 68.9% (SE = 2.6). In hierarchical order, EFS was 45.9% (4.4) in 132 MRD-HR patients, 41.2% (11.9) in 17 patients with no CR at day 33, 36.4% (14.5) in 11 patients with t(4;11), and 74.0% (3.6) in 152 HR patients only for PPR. No statistically significant difference was found for disease-free survival in patients with very HR features [MRD-HR, no CR at day 33, t(4;11) translocation], given hematopoietic stem cell transplantation (HSCT) (n = 66) or chemotherapy only (n = 88), after adjusting for waiting time to HSCT (5.7 months). Patients at HR only for PPR have a favorable outcome. MRD-HR is associated with poor outcome despite intensive treatment and/or HSCT and may qualify for innovative therapies. The study was registered at www.clinicaltrials.gov as #NCT00613457.


Subject(s)
Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Child , Child, Preschool , Combined Modality Therapy , Female , Hematopoietic Stem Cell Transplantation , Humans , Infant , Male , Neoplasm, Residual , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Radiotherapy , Remission Induction , Treatment Outcome
7.
Arch Ital Urol Androl ; 84(3): 141-5, 2012 Sep.
Article in English | MEDLINE | ID: mdl-23210406

ABSTRACT

OBJECTIVES: The aim of this study is to evaluate the fertility in young patients affected by Hodgkin and non-Hodgkin lymphoma, before and after chemotherapy and/or radiotherapy. We conducted a retrospective study to analyse how treatment affects male fertility and a perspective study to assess pre-treatment sperm quality. MATERIALS AND METHODS: 28 patients, treated in our center or referred to our Medically Assisted Procreation Center, from 2002 to 2011, were selected for the retrospective study and asked if interested in their fertility assessment. Semen samples were taken from 11 patients (mean age 31.55: range 20-45); other possible causes of impaired fertility were excluded. We analyzed pretreatment semen samples of 61 patients (mean age 29.08 +/- 9.5) affected by leukaemia or lymphoma that were selected for the perspective study and referred to the Sperm Bank of Pordenone. All semen samples were analysed accordingly to 1999 World Health Organization guidelines. RESULTS: In the retrospective study all semen samples of the 11 patients selected were altered. Six patients treated with high dose alkylating agents and abdominal/pelvic radiotherapy were found azoospermic, 3 with severe oligoasthenozoospermic, 1 oligoteratozoospermic and 1 asthenozoospermic. In the perspective study pretreatment semen quality was poor in most of the samples of the 61 patients selected. Normozoospermia was observed in 14% of patients affected by Hodgkin lymphoma and in 25% affected by non-Hodgkin lymphoma. CONCLUSION: Chemotherapy, radiotherapy or their combination are followed by a temporary but sometimes irreversible reduction of fertility potential. Pre-treatment semen quality is acceptable to proceed with cyopreservation techniques. Sperm cryopreservation should be offered to all post puberal male patients who have not yet conceived before treatment with gonado-toxic agents.


Subject(s)
Hodgkin Disease/complications , Hodgkin Disease/therapy , Infertility, Male/etiology , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/therapy , Adult , Humans , Male , Middle Aged , Prospective Studies , Retrospective Studies , Young Adult
8.
Ital J Pediatr ; 37: 44, 2011 Sep 18.
Article in English | MEDLINE | ID: mdl-21923939

ABSTRACT

BACKGROUND: There has been a noticeable annual increase in the number of children coming to Italy for medical treatment, just like it has happened in the rest of the European Union. In Italy, the assistance to children suffering from cancer is assured by the current network of 54 centres members of the Italian Association of Paediatric Haematology and Oncology (AIEOP), which has kept records of all demographic and clinical data in the database of Mod.1.01 Registry since 1989. METHODS: We used the information stored in the already mentioned database to assess the impact of immigration of foreign children with cancer on centres' activity, with the scope of drawing a map of the assistance to these cases. RESULTS: Out of 14,738 cases recorded by all centres in the period from 1999 to 2008, 92.2% were born and resident in Italy, 4.1% (608) were born abroad and living abroad and 3.7% (538) were born abroad and living in Italy. Foreign children cases have increased over the years from 2.5% in 1999 to. 8.1% in 2008.Most immigrant children came from Europe (65.7%), whereas patients who came from America, Asia and Oceania amounted to 13.2%, 10.1%, 0.2%, respectively. The immigrant survival rate was lower compared to that of children who were born in Italy. This is especially true for acute lymphoblastic leukaemia patients entered an AIEOP protocol, who showed a 10-years survival rate of 71.0% vs. 80.7% (p < 0.001) for immigrants and patients born in Italy, respectively. CONCLUSIONS: Children and adolescents are an increasingly important part of the immigration phenomenon, which occurs in many parts of the world. In Italy the vast majority of children affected by malignancies are treated in AIEOP centres. Since immigrant children are predominantly treated in northern Italy, these centres have developed a special expertise in treating immigrant patients, which is certainly very useful for the entire AIEOP network.


Subject(s)
Emigrants and Immigrants/statistics & numerical data , Neoplasms/ethnology , Adolescent , Africa/ethnology , Asia/ethnology , Child , Child, Preschool , Databases, Factual , Ethnicity/statistics & numerical data , Europe, Eastern/ethnology , European Union/statistics & numerical data , Female , Humans , Incidence , Infant , Infant, Newborn , Italy/epidemiology , Male , Neoplasms/mortality , North America/ethnology , Oceania/ethnology , Prevalence , Retrospective Studies , South America/ethnology , Survival Rate
9.
Pediatr Blood Cancer ; 54(4): 532-7, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20049928

ABSTRACT

BACKGROUND: Teratoma with a malignant somatic component (TMSC) is rare but described in adults, whereas information on pediatric presentation is sparse. PROCEDURE: The Associazione Italiana Ematologia Oncologia Pediatrica identified 14 cases of TMSC. Clinical files and pathology specimens were reviewed. RESULTS: The series (9 female, 5 male) showed the following disease: testis (2), sacrococcygeal (3), ovary (3), retroperitoneum (3), mediastinum (2), and foot soft tissue (1). Distribution of the somatic component was: carcinoma (4), pancreatic neuroendocrine tumor (1), neuroblastoma (3), rhabdomyosarcoma (3), rhabdomyosarcoma plus liposarcoma, chondrosarcoma, neurogenic sarcoma (1), chondrosarcoma plus neuroectodermal sarcoma (1), malignant peripheral nerve sheath tumor (1). Three patients were in stage I, four in stage II, three in stage III, and four in stage IV. All but one patient underwent surgery and only females showed carcinoma components. Nine patients relapsed or progressed and eight died. Six patients are alive and disease-free. Two patients underwent complete resection and four were treated based on transformed histologies. Relapse-free and overall survival rates were 35.7% and 42.8%, respectively (median follow-up, 31 months). CONCLUSIONS: Prognosis for germ cell tumors (GCTs) containing MSC is worse than that for GCTs. The pediatric disease appears to be more heterogeneous in tumor site distribution and MSC histology than in adults. Our series suggests no effects of age, histology, or gender on outcome. Surgery has an essential role in localized disease, with complete resection highly desirable. Chemotherapy optimized for histology should include reagents directed to the somatic malignancy, if chemosensitive. Malignant GCT warrants GCT-directed chemotherapy.


Subject(s)
Teratoma/pathology , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Italy , Male , Neoplasm Staging , Prognosis , Retrospective Studies , Teratoma/mortality , Teratoma/surgery , Treatment Outcome
10.
Pediatr Blood Cancer ; 53(6): 984-91, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19621425

ABSTRACT

BACKGROUND: Glucocorticoids (GCs) play a fundamental role in the treatment of pediatric acute lymphoblastic leukemia (ALL), but therapy with these agents often results in a number of severe side effects. The aim of our study was to evaluate the association between polymorphisms of genes encoding for proteins involved in the pharmacokinetics/pharmacodynamics of these drugs and the occurrence of side effects, in particular infections, in a small population of ALL children. PROCEDURE: Common polymorphisms of NR3C1, ABCB1, glutathione-S-transferase (GST)-M1, GST-P1, GST-T1, and IL-10 genes were analyzed in 36 pediatric patients with ALL, treated according to the AIEOP-BMF ALL 2000 study protocol. Toxicities occurring during the induction and reinduction periods were assessed and their association with genotypes was evaluated. RESULTS: In univariate analysis, the risk of severe infections was increased in subjects with the GST-M1 null genotype, while patients with the GST-M1 normal genotype had significantly more moderate degree infections. The results were confirmed by multivariate analysis. Selection from the reference models of independent variables based on Akaike Information Criteria (AIC) scores maintained the GST-M1 genotype variable in the model to predict severe infections, and the ABCB1 C3435T and GST-M1 genotype variables in the model for moderate infections. CONCLUSIONS: GST-M1 genotype may influence the severity of infections in ALL children during GC administration.


Subject(s)
Glucocorticoids/administration & dosage , Glutathione Transferase/genetics , Polymorphism, Genetic , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Child , Child, Preschool , Dexamethasone/administration & dosage , Female , Glucocorticoids/toxicity , Humans , Infant , Infections/chemically induced , Infections/genetics , Male , Methotrexate/administration & dosage , Pharmacogenetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Prednisone/administration & dosage
11.
Epidemiol Prev ; 33(4-5): 161-8, 2009.
Article in Italian | MEDLINE | ID: mdl-20124631

ABSTRACT

OBJECTIVE: to report and analyse time trends in cancer incidence among children (0-14 years of age), adolescents (15-19 years) and young adults (20-24 years) living in the Italian province of Trieste (2003 population, 242,000), between 1972 and 2003. DESIGN: population-based study of descriptive epidemiology. SETTING AND PARTICIPANTS: the new cases of cancer diagnosed to the residents of the province of Trieste below 25 years of age were extracted from the database of the Trieste Cancer Registry (period 1972-1994) and from the database of the Friuli-Venezia Giulia Cancer Registry (period 1995-2003), according to the International Classification of Childhood Cancer (3rd edition). MAIN OUTCOME MEASURES: age-specific and age-standardized (Italian 1981 census population as standard) incidence rates, by diagnostic group, sex and period of diagnosis. Time trend in incidence was analysed by using a Poisson regression model adjusted for calendar year, sex and 5 year age-group, and was expressed as annual percent change (APC) in rates. RESULTS: in the period 1972-2003, the new cases of cancer were 168 in the age-group 0-14 years, 79 in the age-group 15-19 years and 111 in the age-group 20-24 years, while the person-years at risk were respectively: 1,050,027; 431,673; 496,450. The APC in the incidence of all cancers combined was 2.3% (IC 95% 0.6%-3.9%) in children, 4.4% (IC 95% 1.8%-7.1%) in adolescents and 5.1% (IC 95% 2.8%-7.5%) in young adults. Hodgkin lymphomas (APC =12.7%; IC 95% 2.6%-23.7%; 7 cases) in the age-group 0-14 years, skin melanomas and carcinomas (APC =8.2%; IC 95% 4.5%-12.0%; 49 cases) and central nervous system tumours (APC = 6.4%; IC 95% 1.5%-11.5%; 25 cases) in the age-group 15-24 years were the malignancies characterised by the highest increase in incidence. CONCLUSION: the increase in incidence rates observed in this study can be only partly explained by the small number of ascertained cases, by an improvement in diagnostic techniques and by more efficient registration. However, few environmental and hereditary factors are consistently associated with cancers affecting young people. Therefore, it is imperative to continue to carry out descriptive and analytical studies with primary prevention as the ultimate aim.


Subject(s)
Neoplasms/epidemiology , Age of Onset , Bias , Child , Child, Preschool , Female , Humans , Incidence , Infant , Infant, Newborn , Italy/epidemiology , Linear Models , Male , Morbidity/trends , Neoplasms/diagnosis , Poisson Distribution , Registries/statistics & numerical data , Retrospective Studies , Young Adult
12.
Eur J Cancer ; 44(9): 1202-9, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18440800

ABSTRACT

BACKGROUND: The outcome of patients with non-extremity synovial sarcoma (SS) is generally worse than that of patients with limb tumours. METHODS: The present study analysed a series of 115 consecutive SS patients treated in Italian paediatric protocols (period 1979-2005), mainly focusing on the 30 cases arising from 'axial' sites (16 head-neck, 8 trunk, 4 lung-pleura and 2 retroperitoneum). RESULTS: Initial gross resection was achieved in 40% of axial cases and in 80% of limb SS (p<0.0001). Five-year EFS and overall survival (OS) were, respectively, 43.3% and 55.1% for axial SS, and 69.6% (p=0.0068) and 84.0% (p=0.0004) for extremity SS. Local progression/recurrence was the cause of treatment failure in 75% of relapsing patients axial disease. CONCLUSIONS: Our findings emphasise that children and adolescents with SS originating at non-extremity locations have a worse prognosis than those with limb SS. Tumour site should be considered when defining a risk-adapted treatment strategy for SS.


Subject(s)
Sarcoma, Synovial/therapy , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Child , Child, Preschool , Combined Modality Therapy/mortality , Disease-Free Survival , Female , Humans , Infant , Italy/epidemiology , Male , Neoplasm Staging , Neoplasm, Residual , Prospective Studies , Sarcoma, Synovial/mortality , Sarcoma, Synovial/pathology , Treatment Outcome
13.
Pediatr Surg Int ; 23(4): 315-22, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17333214

ABSTRACT

Teratoma is the most common germ cell tumour in childhood; mature (MT) and immature teratomas (IT) are benign tumours, but if they recur, they can be in some cases malignant. The aim of this paper is to evaluate Italian patients with MT and IT enrolled from 1991 to 2001, in a prospective multicentric study. One hundred and eighty-three patients, observed in 15 Italian Centers of Paediatric Oncology and three Paediatric Surgical Units were enrolled. Clinical data, treatment and results were all analysed. Initial evaluation and subsequent follow up included clinical examination, tumour markers and imaging procedures. Surgical resection was recommended for all the tumours. Histology was centrally reviewed and IT was classified as grading 1-3. Chemotherapy (CT) with Vinblastine, D: -actinomycin and cyclophosphamide was indicated for extra-testicular IT grade 2 or 3. MT was diagnosed in 127 patients (93 F and 34 M, age 1-192 months, median 24): 58 patients had gonadic tumour (23 testicular, 35 ovaric), 69 extragonadic (45 sacrococcygeal, 11 mediastinic, 7 retroperitoneal, 6 in other sites). A complete resection was performed in 117 patients, a partial resection in eight patients and biopsy in one. IT was diagnosed in 56 patients (34 F, 22 M, age 1-168 months, median 7). The T grading was 1 in 14 cases, 2 in 26, 3 in 16; 28 had gonadic T (17 ovary, 11 testis), 28 extragonadic (sacrococcygeal 19, mediastinic 3, retroperitoneal 2, other sites 4). CT was administered in eight patients; 15/182 patients relapsed (1 in a metastatic site) and in 5/15 the relapse showed malignant histology. Seven MT (5.5%) relapsed (five sacrococcygeal, one retroperitoneal, one mediastinic): surgery at diagnosis had been complete in five and with residual in two; the relapse was malignant in two patients with sacrococcygeal (sc) tumours, who had a complete resection and a partial resection respectively. Eight IT (14.2%) relapsed (four ovary, three sc, one retroperitoneal). The initial surgical resection had been complete in one, with residual in six, and a biopsy had been performed in one. A malignant recurrence occurred in two patients with sc tumours (after partial resection in one and after biopsy + CT in one) and in one patient with ovarian IT after a partial resection. All the patients underwent surgical excision of the recurred mass; CT according to Protocol for Malignant GCT was administered to those who had malignant recurrence; 122/126 patients with MT and 53/56 with IT are alive without disease with a follow up of 8-144 months (median 56). Two patients with malignant relapse (one with sc MT, one with sc IT) died because of the progression of the disease. Another two died due to severe malformations (one MT, one IT) and three were lost to follow up (two MT, one IT). The overall survival (OS) at 10 years is 98% (95% CI 93.9-99.4); the event free survival (EFS) is 90.4% (95 CI 84.8-94.0). At Cox analysis no significant difference in EFS was found regarding age and site of the primary tumour, while females (P = 0.011), patients with grade 1-3 histology (P = 0.025) and patients with incomplete resection appeared at higher risk of death or relapse (P < 0.001), with a seven, three and eightfold increase in risk, respectively. Our data showed that incomplete resection and female gender are important risk factors for relapse or death, more so than IT histology. The number of patients treated with CT is not sufficient to evaluate the efficacy of CT in avoiding malignant relapse.


Subject(s)
Ovarian Neoplasms/epidemiology , Teratoma/epidemiology , Testicular Neoplasms/epidemiology , Age Distribution , Child , Child, Preschool , Combined Modality Therapy , Female , Humans , Incidence , Infant , Infant, Newborn , Italy/epidemiology , Male , Neoplasm Staging , Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , Prospective Studies , Teratoma/pathology , Teratoma/therapy , Testicular Neoplasms/pathology , Testicular Neoplasms/therapy
14.
Pediatr Blood Cancer ; 47(5): 560-6, 2006 Oct 15.
Article in English | MEDLINE | ID: mdl-16395684

ABSTRACT

BACKGROUND: Despite the increased survival of children with solid tumors, a significant proportion of cases still relapse following treatment discontinuation, and knowledge about the long-term outcome of this selected group of patients remains incomplete. OBJECTIVE: To describe the long-term outcome of children treated for a solid tumor who relapsed after the elective end of therapy, and to explore factors associated with survival. METHODS: All patients with the selected diagnoses-Hodgkin disease (HD), neuroblastoma (NB), tumor of the central nervous system (CNS), Wilms tumor (WT), or soft tissue sarcoma (STS)-enrolled in the Italian Pediatric Off-Therapy Registry in the period 1980-1998 were evaluated. Out of 3,927 patients, 694 had relapsed after treatment suspension; 639 were available for analysis. Survival and event-free survival were estimated by the Kaplan-Meier method. The log-rank test was used to assess differences in survival among the various types of cancer considered. Multivariate Cox proportional hazards analysis was adopted to explore possible prognostic factors. RESULTS: There were 335 deaths: most of them (93%) were related to the primary cancer. The overall survival rate after relapse was 38% (95% CI 33-42) at 5 years, and 32% (95% CI 27-36%) at 15 years, while event free survival was 31% (95% CI 26-35) and 26% (95% CI 22-30%), respectively. There were significant differences according to the original diagnosis, with patients with HD doing better, and those with NB, CNS, and STS worse. No improvement of prognosis was evident over time. Post-relapse stem cell transplantation was associated with decreased risk of death only in the first year, not thereafter. CONCLUSIONS: Overall, patients with solid tumors who relapse after treatment discontinuation have a poor outcome, but significant differences exist according to the tumor types.


Subject(s)
Hodgkin Disease/diagnosis , Nervous System Neoplasms/diagnosis , Neuroblastoma/diagnosis , Registries , Sarcoma/diagnosis , Wilms Tumor/diagnosis , Adolescent , Child , Child, Preschool , Cohort Studies , Disease-Free Survival , Female , Follow-Up Studies , Hodgkin Disease/therapy , Humans , Infant , Infant, Newborn , Italy , Male , Nervous System Neoplasms/therapy , Neuroblastoma/therapy , Prognosis , Recurrence , Risk Factors , Sarcoma/therapy , Stem Cell Transplantation , Survival Rate , Transplantation, Homologous , Treatment Outcome , Wilms Tumor/therapy
15.
Cancer ; 104(10): 2133-40, 2005 Nov 15.
Article in English | MEDLINE | ID: mdl-16211546

ABSTRACT

BACKGROUND: Childhood anaplastic large cell lymphoma (ALCL) is a well defined entity with a rather poor prognosis. Different approaches have been adopted in the treatment of ALCL in various cooperative trials, including short high-dose intensive therapy and leukemia-like protocols. In the early 1990s, the Italian Association of Pediatric Hematology and Oncology (AIEOP) initiated a multicenter trial for the treatment of ALCL based on a modified LSA2-L2 protocol. METHODS: Thirty-four consecutive eligible children with newly diagnosed ALCL were enrolled in the AIEOP LNH-92 protocol. Treatment was comprised of an induction of remission phase, followed by consolidation and maintenance for a total duration of 24 months, independently of disease stage. RESULTS: Thirty of 34 patients (88%) achieved complete disease remission and 8 patients experienced disease recurrence. With a median follow-up of 8.4 years, the probabilities of survival and event-free survival were 85% (range, 79-91%) and 65% (range, 57-73%), respectively. Therapy was well tolerated and hematologic toxicity was the most frequent toxicity. CONCLUSIONS: The leukemia-like protocol AIEOP LNH-92 was found to be an effective treatment for childhood ALCL. Its long duration may be beneficial to specific patient subgroups, but optimal treatment duration in ALCL remains to be elucidated.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/mortality , Adolescent , Child , Child, Preschool , Cyclophosphamide/therapeutic use , Daunorubicin/therapeutic use , Disease-Free Survival , Female , Humans , Immunohistochemistry , Leukemia/therapy , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Methotrexate/therapeutic use , Neoplasm Staging , Prednisone/therapeutic use , Survival Analysis , Treatment Outcome , Vincristine/therapeutic use
16.
Int J Cancer ; 115(5): 814-21, 2005 Jul 10.
Article in English | MEDLINE | ID: mdl-15729697

ABSTRACT

We carried out a cohort study in the Italian province of Trieste (2001 population, 242,000) to ascertain whether the risk of a subsequent primary cancer among 265 individuals diagnosed with a first malignancy at ages up to 25 years between 1971 and 1993 differed from that in the general population and to evaluate the effect of cancer family history, quantified by the family risk index (FRI), on the occurrence of second primaries. During the follow-up (median duration = 10 years; 25th-75th percentile = 2-16), 15 cohort members developed a second cancer vs. 1.60 expected for a standardized incidence ratio (SIR) of 9.4 (p < 0.0001). The overall SIR fell to 4.7 (p = 0.004) after excluding the 8 patients with well-known cancer-predisposing conditions (SIR = 300.0; p < 0.0001) and the 50 with a positive family history (FRI >/= 1.0) of malignant tumors (SIR = 20.0; p < 0.0001). Among 114 patients treated with radiotherapy and chemotherapy for their first neoplasms and not affected by predisposing disorders, 23 with a positive family history of cancer showed a 6.4-fold excess risk of second primaries (p = 0.008) compared with 91 with a negative history (FRI < 1.0). It is imperative that clinicians carefully and regularly evaluate cancer family history of young patients with malignancies. This would enable them to identify possible individual and familial features in patients at higher risk of multiple primaries and to adopt more suitable preventive and therapeutic measures.


Subject(s)
Genetic Predisposition to Disease , Neoplasms, Second Primary/etiology , Neoplasms, Second Primary/genetics , Adult , Age of Onset , Child , Child, Preschool , Cohort Studies , Female , Humans , Infant , Infant, Newborn , Italy , Male , Medical History Taking , Neoplasms, Second Primary/epidemiology , Pedigree , Risk Factors
17.
Cancer ; 100(8): 1758-65, 2004 Apr 15.
Article in English | MEDLINE | ID: mdl-15073867

ABSTRACT

BACKGROUND: Survivors of childhood malignancies have an increased risk of developing second malignant neoplasms (SMN) due to their prior treatment and/or genetic susceptibility. A small proportion of SMNs are soft tissue sarcomas (STS), whose prognosis is generally thought to be poor, though publications on such patients' treatment and outcome is limited. METHODS: The authors analyzed 25 patients who were registered for the Italian Cooperative Group protocols for pediatric STS from 1979 to 2000. The primary tumor was STS in five patients; Hodgkin disease in five patients; leukemia in four patients; retinoblastoma, neuroblastoma, and Wilms tumor in two patients each; and other tumor types in five patients. SMNs occurred after a median of 8 years (range, 1.9-15.0 years) and included rhabdomyosarcoma (RMS) in 4 patients, malignant peripheral nerve sheath tumor in 4 patients, extraosseous Ewing family tumor (EFT) in 4 patients, leiomyosarcoma in 3 patients, fibrosarcoma in 2 patients, synovial sarcoma in 2 patients, and other tumor types in 6 patients. Treatment generally was administered according to the guidelines for primary STS. RESULTS: Seven non-RMS patients with STS underwent surgery alone, whereas 18 patients received chemotherapy and 8 patients received radiotherapy. Retreatment was feasible with acceptable toxicity. Fifteen patients were alive in complete remission of their SMN at the time of last follow-up. Responses to chemotherapy and survival were satisfactory for patients with tumors such as RMS and EFT. Complete tumor resection was correlated with a favorable prognosis in patients with other types of STS and in patients with postirradiation sarcoma. Two patients developed a third malignancy. CONCLUSIONS: Although prior treatment may hinder the management of these patients, pediatric STS second malignancies can be cured using the same strategies used for de novo pediatric sarcomas. Long-term follow-up is mandatory given the risks of further malignancies and more severe, treatment-related side effects.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neoplasms, Second Primary , Sarcoma/surgery , Soft Tissue Neoplasms/surgery , Adolescent , Adult , Child , Child, Preschool , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Male , Prognosis , Sarcoma/drug therapy , Sarcoma/etiology , Sarcoma/radiotherapy , Soft Tissue Neoplasms/drug therapy , Soft Tissue Neoplasms/etiology , Soft Tissue Neoplasms/radiotherapy , Survival Analysis , Treatment Outcome
19.
Med Pediatr Oncol ; 41(5): 417-25, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14515380

ABSTRACT

BACKGROUND AND AIMS: About 20% of patients with germ cell tumor (GCT) are still resistant to therapy. To investigate which features are present in resistant patients, a multicenter study on GCT in children was undertaken to correlate clinical and laboratory parameters with the outcome. METHODS: Patients aged less than 16 years, with histologically proven extracranial GCT were included. RESULTS: Ninety-five patients (median age 33 months, 45 males) were eligible. The site of the primary tumor was gonadal in 59, extragonadal in 36. The stage was I in 39; II in 5; IIIa (microscopic residue) in 7; IIIb (macroscopic residue) in 16; IIIc (unresectable) in 13; IV in 15. The treatment was surgery alone in 31; surgery plus radiotherapy in 1; chemotherapy +/- surgery in 63. Post-chemotherapy resection in 19 (10 complete, 9 partial). The chemotherapy regimen was carboplatin 400 mg/m2/day on days 1, 2; etoposide 150 mg/m2/day on days 1, 2; ifosfamide 1,500 mg/m2/day on days 21, 22; dactinomycin 1.5 mg/m2/day on day 21; vincristine 1.5 mg/m2/day on day 21. Three patients died because of toxicity and two non-responders (to primary chemotherapy), died of progression; among the remaining 90 patients 20 relapsed, 9 are in second remission, 2 are alive with disease, and 9 died of disease progression (one from progression and intracranial hemorrhage). Overall survival was 82.7% and event-free survival: 71.5%. Survival according to: (a) site: testis: 100%; ovary: 88%; sacrococcyx: 69.6%; other sites: 33.3% (P < 0.001); (b) stage: I and II: 100%; IIIa: 83.3%; IIIb: 84.6%; IIIc: 60.6%; IV: 53.2% (P < 0.001); (c) AFP levels: normal: 85.5%; 42-9,470 ng/ml: 84.6%; >/=10,000 ng/ml: 58.7% (P = 0.02). All the pts who had complete resection of the primary tumor at diagnosis or at delayed surgery, remained in remission. CONCLUSIONS: Multivariate analysis showed that the primary site of tumor was the only independent prognostic factor for survival and EFS.


Subject(s)
Germinoma/pathology , Germinoma/therapy , Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , Testicular Neoplasms/pathology , Testicular Neoplasms/therapy , Adolescent , Age Distribution , Child , Child, Preschool , Cohort Studies , Combined Modality Therapy , Confidence Intervals , Female , Germinoma/epidemiology , Humans , Incidence , Italy/epidemiology , Male , Multivariate Analysis , Neoplasm Staging , Ovarian Neoplasms/epidemiology , Probability , Prognosis , Retrospective Studies , Risk Assessment , Sex Distribution , Survival Analysis , Testicular Neoplasms/epidemiology , Treatment Outcome
20.
Haematologica ; 88(7): 747-53, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12857552

ABSTRACT

BACKGROUND AND OBJECTIVES: Osteonecrosis (ON) is a potentially disabling complication of combination chemotherapy including high doses of steroids. The incidence and main risk factors for symptomatic ON have been investigated in a large group of children treated with high-dose steroids, prednisone and dexamethasone for childhood acute lymphoblastic leukemia (ALL). DESIGN AND METHODS: From May 1995 to December 1999, 1421 patients <18 years old, with newly diagnosed non-B ALL, were registered in the AIEOP-ALL 95 study. Their data were reviewed to identify patients who developed symptomatic ON. For those who were positively identified additional data were requested concerning ON-related symptoms, treatment and outcome. RESULTS: Overall, 15 of the 1421 patients developed symptomatic ON (1.1%) in a total of 29 sites. The estimated 5-year cumulative risk for clinically diagnosed ON was 1.6% (SE 0.4). The incidence was significantly higher among females (p=0.01) and older patients, with a peak rate of 7.4% (2.3) among those aged 10 to 17 years (p<0.0001). When the two factors, i.e. age and gender were combined, there was a striking increase in the risk among female patients aged 10 to 17 years. The median time between the diagnosis of ALL and that of ON was 17 months (range 8-45). The hip was the most frequently involved (19/29) site. INTERPRETATION AND CONCLUSIONS: Symptomatic ON occurred in only 1.1% of patients treated with BFM-type, intensive chemotherapy for childhood ALL. Female adolescents appear to be the subset of patients with the highest risk of ON, especially when categorized as having high risk leukemia and thus administered higher cumulative doses of dexamethasone.


Subject(s)
Antineoplastic Agents, Hormonal/adverse effects , Osteonecrosis/chemically induced , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Antineoplastic Agents, Hormonal/therapeutic use , Child , Dexamethasone/adverse effects , Dexamethasone/therapeutic use , Drug Therapy, Combination , Female , Humans , Incidence , Male , Osteonecrosis/diagnosis , Osteonecrosis/epidemiology , Osteonecrosis/therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Prednisone/adverse effects , Prednisone/therapeutic use , Risk Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...